No. As I warned before the first partnership and the first term sheet, don't build up unrealistic expectations. This is why you guys get frustrated.
We might see a B-OM deal by November. It we do, it is very likely small like the B-UP deal with AS. The company even explained it would not be with a (deep-pocket) BP. And this makes sense. Our deal with AS was small in scope and size and they originally passed on B-OM. Pharmas aren't throwing money at this indication, it's very niche, despite the AIF implications. Even though B is a 'platform', we're having to cobble together development deals. This is unfortunate, but we do what we can.
You'll note how easily some folks go from "Leo is a genius!!!" to "Wahhh, Leo isn't working hard!!!" Has nothing to do with reality. Has everything to do with share price. These are not good investors for biotech. It's not for penny stock speculators.
Btw, Leo is neither a genius nor lazy. He's a nice hard working man managing a young and weally funded biotech that has some promising drugs and big set backs.
There is one thing in your post that was correct: we made some good progress so far this year.